دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes
Prakriti Gaba, MD1; Evald H. Christiansen, MD2; Per H. Nielsen, MD2; Sabina A. Murphy, MPH1; Patrick T. O’Gara, MD1,9; Peter K. Smith, MD3; Patrick W. Serruys, MD4; A. Pieter Kappetein, MD5; Seung-Jung Park, MD6; Duk-Woo Park, MD6; Gregg W. Stone, MD7; Joseph F. Sabik, MD8; Marc S. Sabatine, MD, MPH1,9; Niels R. Holm, MD2; Brian A. Bergmark, MD1
doi : 10.1001/jamacardio.2023.1177
July 2023, Vol 8, No. 7, Pages 628-710
Importance Patients with left main coronary artery disease presenting with an acute coronary syndrome (ACS) represent a high-risk and understudied subgroup of patients with atherosclerosis.
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction
Javed Butler, MD, MPH, MBA1,2; Muhammad Shariq Usman, MD1; Gerasimos Filippatos, MD, PhD3; João Pedro Ferreira, MD, PhD4; Michael Böhm, MD5; Martina Brueckmann, MD6,7; James L. Januzzi, MD8; Sanjay Kaul, MD9; Ileana L. Piña, MD, MPH10; Piotr Ponikowski, MD, PhD11; Michele Senni, MD12; Mikhail Sumin, MD, PhD6; Subodh Verma, MD, PhD13; Liliana Zaremba-Pechmann, PhD14; Stuart J. Pocock, PhD15; Milton Packer, MD16,17; Stefan Anker, MD, PhD18,19
doi : 10.1001/jamacardio.2023.1090
Importance The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in interaction with background diuretic therapy in patients with heart failure and preserved ejection fraction (HFpEF).
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US
Jacob B. Pierce, MD, MPH1; Muthiah Vaduganathan, MD, MPH2; Gregg C. Fonarow, MD3,4; Uchechukwu Ikeaba, MS5; Karen Chiswell, PhD5; Javed Butler, MD, MPH, MBA6,7; Adam D. DeVore, MD, MHS5,8; Paul A. Heidenreich, MD, MS9; Joanna C. Huang, PharmD10; Michelle M. Kittleson, MD, PhD11; Karen E. Joynt Maddox, MD, MPH12; Karthik K. Linganathan, MD10; James J. McDermott, PhD10; Anjali Tiku Owens, MD13; Pamela N. Peterson, MD, MSPH14,15; Scott D. Solomon, MD2; Orly Vardeny, PharmD16; Clyde W. Yancy, MD, MSc17,18; Stephen J. Greene, MD5,8
doi : 10.1001/jamacardio.2023.1266
Importance Clinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwide adoption of SGLT2i for HFrEF in the US is unknown.
Diagnostic and Prognostic Value of Stress Cardiovascular Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease
Fabrizio Ricci, MD, PhD, MSc1,2,3; Mohammed Y. Khanji, MBBCh, PhD3,4,5; Giandomenico Bisaccia, MD1; Alberto Cipriani, MD6; Annamaria Di Cesare, MD7; Laura Ceriello, MD1; Cesare Mantini, MD, PhD1; Marco Zimarino, MD, PhD1; Artur Fedorowski, MD, PhD2,8,9; Sabina Gallina, MD1; Steffen E. Petersen, MD, DPhil, MSc, MPH4,5,10,11; Chiara Bucciarelli-Ducci, MD, PhD12,13
doi : 10.1001/jamacardio.2023.1290
Importance The clinical utility of stress cardiovascular magnetic resonance imaging (CMR) in stable chest pain is still debated, and the low-risk period for adverse cardiovascular (CV) events after a negative test result is unknown.
Genetic Risk Factors Associated With Preeclampsia and Hypertensive Disorders of Pregnancy
Jaakko S. Tyrmi, PhD1,2,3; Tea Kaartokallio, PhD4; A. Inkeri Lokki, PhD4,5; Tiina Jääskeläinen, PhD4,6; Eija Kortelainen, RN4; Sanni Ruotsalainen, PhD7; Juha Karjalainen, PhD7,8,9; Samuli Ripatti, PhD7,9,10; Anna Kivioja, MD1; Triin Laisk, PhD11; Johannes Kettunen, PhD3,12; Anneli Pouta, MD, PhD12; Katja Kivinen, PhD7; Eero Kajantie, MD, PhD13,14,15,16; Seppo Heinonen, MD, PhD17; Juha Kere, MD, PhD18,19; Hannele Laivuori, MD, PhD1,4,7,20; for the FINNPEC Study Group, FinnGen Project, and the Estonian Biobank Research Team
doi : 10.1001/jamacardio.2023.1312
Importance A genetic contribution to preeclampsia susceptibility has been established but is still incompletely understood.
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Alexander Peikert, MD1; Alvin Chandra, MD2; Mikhail N. Kosiborod, MD3; Brian L. Claggett, PhD1; Akshay S. Desai, MD, MPH1; Pardeep S. Jhund, MBChB, MSc, PhD4; Carolyn S. P. Lam, MD5,6; Silvio E. Inzucchi, MD7; Felipe A. Martinez, MD8; Rudolf A. de Boer, MD9; Adrian F. Hernandez, MD10; Sanjiv J. Shah, MD11; Stefan P. Janssens, MD12; Jan Bělohlávek, MD13; C. Jan Willem Borleffs, MD14; Dan Dobreanu, MD15; Anna Maria Langkilde, MD, PhD16; Olof Bengtsson, PhLic16; Magnus Petersson, MD, PhD16; John J. V. McMurray, MD4; Scott D. Solomon, MD1; Muthiah Vaduganathan, MD, MPH1
doi : 10.1001/jamacardio.2023.1342
Importance Dapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. A comprehensive understanding of the responsiveness of individual KCCQ items would allow clinicians to better inform patients on expected changes in daily living with treatment.
Heterogeneity of Lipoprotein(a) Levels Among Hispanic or Latino Individuals Residing in the US
Parag H. Joshi, MD, MHS1; Santica Marcovina, PhD2; Kate Orroth, PhD, MPH3; J. Antonio G. López, MD4; Shia T. Kent, PhD3; Robert Kaplan, PhD5; Katrina Swett, MS6; Daniela Sotres-Alvarez, DrPH7; Bharat Thyagarajan, MD, PhD8; Leandro Slipczuk, MD, PhD6; Tamar Sofer, PhD9; Martha L. Daviglus, MD, PhD10; Gregory A. Talavera, MD, MPH11; Neil Schneiderman, PhD12; Carlos J. Rodriguez, MD, MPH6
doi : 10.1001/jamacardio.2023.1134
Importance Lipoprotein(a) (Lp[a]) is a genetically determined risk-enhancing factor for atherosclerotic cardiovascular disease (ASCVD). The Lp(a) distribution among the diverse Hispanic or Latino community residing in the US has not been previously described, to the authors’ knowledge.
Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy–Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer
Anthony F. Yu, MD1,2; Zachary R. Moore, MD, PhD3; Chaya S. Moskowitz, PhD4; Jennifer E. Liu, MD1,2; Chau T. Dang, MD1,2; Lakshmi Ramanathan, PhD5; Kevin C. Oeffinger, MD6; Richard M. Steingart, MD1,2; Adam M. Schmitt, MD3
doi : 10.1001/jamacardio.2023.1229
Importance Cancer therapy–related cardiac dysfunction (CTRCD) is a potentially serious cardiotoxicity of treatments for ERBB2-positive breast cancer (formerly HER2). Identifying early biomarkers of cardiotoxicity could facilitate an individualized approach to cardiac surveillance and early pharmacologic intervention. Circulating cell-free DNA (cfDNA) of cardiomyocyte origin is present during acute cardiac injury but has not been established as a biomarker of CTRCD.
Titanium-Nitride-Oxide–Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome
Frederic Bouisset, MD1,2; Jussi Sia, MD3; Takuya Mizukami, MD, PhD1,4; Pasi P. Karjalainen, MD, PhD5; Pim A. L. Tonino, MD, PhD6; Nico H. J. Pijls, MD, PhD6; Jan Van der Heyden, MD, PhD7; Hannu Romppanen, MD, PhD8; Kari Kervinen, MD, PhD9; Juhani K. E. Airaksinen, MD, PhD10; Jacques Lalmand, MD, PhD11; Peter Frambach, MD, PhD12; Bruno Roza da Costa, PhD13; Carlos Collet, MD, PhD1; Bernard De Bruyne, MD, PhD1,14; for the TIDES-ACS Study Group
doi : 10.1001/jamacardio.2023.1373
Importance Titanium-nitride-oxide (TiNO)–coated stents show faster strut coverage compared with drug-eluting stents without excessive intimal-hyperplasia observed in bare metal stents. It is important to study long-term clinical outcomes after treatment of patients with an acute coronary syndrome (ACS) by TiNO-coated stents, which are neither drug-eluting stents nor bare metal stents.
The Case for Inclusion of a Lipid Panel in the Standard Precatheterization Laboratory Blood Draw—Stating What Should Be Obvious
Lauren S. Ranard, MD1; Eamon Y. Duffy, MD1; Ajay J. Kirtane, MD, SM1,2
Cardiovascular Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure—Does the Story Begin and End With the Kidney?
Ravi B. Patel, MD, MSc1
A Man Aged 45 Years With Chinese Dragon Sign on Chest Radiography
Molly Balcer, MD1; Shaina Ailawadi, MD1; Damian Valencia, MD1,2
Explanation of Error in the Clinical Challenge, “A Case of Right Bundle Branch Block With Changing Axis�
Robert B. King, MD1; Ramil Goel, MD, FHRS1
When Is a High Lipoprotein (a) Concentration Too High?—The Need for Diverse Population-Based Samples
Sadiya S. Khan, MD, MSc1,2
